Data / Federal grants / PAR-27-109
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health (Department of Health and Human Services) expects to post this opportunity around September 1, 2026, with applications due around March 4, 2027. It lists awards of up to $600,000, 4 awards expected.
SpecStream is the live web data engine for teams and agents. It reads every open and forecast federal opportunity on Grants.gov each morning, and this page is that reading. Describe your organization once and the grants that fit arrive in your sheet, CRM, Slack or agent as they are posted.
Key facts
- Opportunity number
- PAR-27-109
- Status
- Forecast
- Posted
- June 10, 2026
- Closes
- March 4, 2027
- Award ceiling
- $600,000
- Award floor
- $300,000
- Expected awards
- 4
- Cost sharing
- Not required
- Funding instrument
- Grant
- Category
- Health
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Contact
- National Institute of Arthritis and Musculoskeletal and Skin Diseases · [email protected] · Please contact via e-mail.
Who can apply
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal governments (Federally recognized)
- Private institutions of higher education
- Public housing authorities/Indian housing authorities
- Special district governments
- State governments
- Independent school districts
- Public and State controlled institutions of higher education
- County governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- City or township governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
What the agency says
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for Exploratory Clinical Trials Grants Program in the mission areas of NIAMS. The goal of the NIAMS clinical trial program is to support research leading to the prevention or reduction of symptoms and improve outcomes and function in patients with rheumatic, musculoskeletal, or skin conditions or diseases. The purpose of the Exploratory Clinical Trials Grants Program is to foster clinical trials that will lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these conditions or diseases. This Exploratory Clinical Trials Grants Program is designed to facilitate the execution of short-term, interventional studies. The Program is intended to support a range of exploratory studies, from proof-of-concept/first in human to Phase I and Phase II clinical trials. Such studies must meet the NIH definition of a clinical trial and be feasible within the time and budget constraints of this NOFO. A high priority is the use of such studies to stimulate the translation of promising research developments from laboratory, preclinical, and early human testing into clinical practice. Examples of research areas of interest include, but are not limited to: Conducting early-stage clinical trials, such as but not limited to; first in human, dose-finding or escalation/tolerability/safety/efficacy studies with drugs, biologics, devices, behavioral interventions, and/or physical therapy for treatment of arthritis, musculoskeletal, or skin conditions or diseases. Clinical trials to provide data required to support a future, more robust clinical trial whose aim is to help establish the safety and efficacy or effectiveness of an intervention. Clinical trials in rare diseases where the number of potential study participants is limited. Clinical trials to determine the predictive value of a potential biomarker.
Other open grants from the Department of Health and Human Services
| Opportunity | Status | Closes | Award ceiling | Total funding | Record |
|---|---|---|---|---|---|
| Long-term health outcomes of people living with spina bifida CDC-RFA-DD-26-0222 | Open | Oct 26 | $300,000 | $3,000,000 | grants.gov |
| GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed) RFA-HG-27-011 | Open | Oct 30 | $1,250,000 | $2,000,000 | grants.gov |
| GREGoRi Innovation Projects (U01 Clinical Trial Optional) RFA-HG-27-013 | Open | Oct 30 | $500,000 | $7,500,000 | grants.gov |
| GREGoRi Technology Integration Center (U01, Clinical Trials Optional) RFA-HG-27-012 | Open | Oct 30 | $2,250,000 | $3,000,000 | grants.gov |
| HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required) PAR-27-045 | Open | Oct 30 | grants.gov | ||
| Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) PAR-24-280 | Open | Nov 2 | grants.gov |
All grants open to Tribal organizations · All grants open to Nonprofits without 501(c)(3) status · All grants open to Tribal governments · Everything closing in March 2027
Read from the Grants.gov API, last updated 2026-10-23. The agency's notice on Grants.gov is the official record; check it before you apply.